select a format

Single User License
USD 3500 INR 224245
Site License
USD 7000 INR 448490
Corporate User License
USD 10500 INR 672735

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Tumor Necrosis Factor Receptor Superfamily Member 5 B-Cell Surface Antigen CD40 or CD40L Receptor or CD40-Pipeline Review, H1 2016

Tumor Necrosis Factor Receptor Superfamily Member 5 B-Cell Surface Antigen CD40 or CD40L Receptor or CD40-Pipeline Review, H1 2016


  • Products Id :- GMDHC0055TDB
  • |
  • Pages: 69
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Pipeline Review, H1 2016', provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) targeted therapeutics

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Overview 8

Therapeutics Development 9

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Products under Development by Stage of Development 9

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Products under Development by Therapy Area 10

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Products under Development by Indication 11

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Pipeline Products Glance 13

Late Stage Products 13

Early Stage Products 14

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Products under Development by Companies 15

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Products under Development by Universities/Institutes 18

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Therapeutics Assessment 20

Assessment by Monotherapy/Combination Products 20

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Companies Involved in Therapeutics Development 27

Alligator Bioscience AB 27

Apexigen, Inc. 28

Apogenix GmbH 29

Boehringer Ingelheim GmbH 30

Bristol-Myers Squibb Company 31

Celldex Therapeutics, Inc. 32

F. Hoffmann-La Roche Ltd. 33

Kyowa Hakko Kirin Co., Ltd. 34

Novartis AG 35

Seattle Genetics, Inc. 36

Zyrnat Biotherapeutics SL 37

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Drug Profiles 38

2C-10-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ADC-1013-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

APG-1233-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

APX-005M-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BI-655064-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

bleselumab-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

BMS-986090-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

CFZ-533-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

FFP-104-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

KGYY-15-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Monoclonal Antibodies to Agonize CD40 for Lymphoma-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

RG-7876-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

SEA-CD40-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Vaccine to Target CD40 for Membranous Glomerulonephritis-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

ZY-11-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Dormant Projects 57

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Discontinued Products 60

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40)-Featured News & Press Releases 61

Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 61

Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 61

Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 62

Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 62

Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 63

Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M 64

May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform 64

Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial 65

Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial 65

Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors 66

Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply 66

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Figures

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Top 10 Indication, H1 2016 11

Comparative Analysis by Early Stage Products, H1 2016 14

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Mechanism of Actions, H1 2016 21

Number of Products by Stage and Mechanism of Actions, H1 2016 21

Number of Products by Routes of Administration, H1 2016 23

Number of Products by Stage and Routes of Administration, H1 2016 23

Number of Products by Molecule Types, H1 2016 25

Number of Products by Stage and Molecule Type, H1 2016 25

List of Tables

Number of Products under Development for, H1 2016 9

Number of Products under Development by Therapy Area, H1 2016 10

Number of Products under Development by Indication, H1 2016 11

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Early Stage Products, H1 2016 14

Number of Products under Development by Companies, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Development by Companies, H1 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H1 2016 18

Products under Investigation by Universities/Institutes, H1 2016 19

Assessment by Monotherapy/Combination Products, H1 2016 20

Number of Products by Stage and Mechanism of Action, H1 2016 22

Number of Products by Stage and Route of Administration, H1 2016 24

Number of Products by Stage and Molecule Type, H1 2016 26

Pipeline by Alligator Bioscience AB, H1 2016 27

Pipeline by Apexigen, Inc., H1 2016 28

Pipeline by Apogenix GmbH, H1 2016 29

Pipeline by Boehringer Ingelheim GmbH, H1 2016 30

Pipeline by Bristol-Myers Squibb Company, H1 2016 31

Pipeline by Celldex Therapeutics, Inc., H1 2016 32

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 33

Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 34

Pipeline by Novartis AG, H1 2016 35

Pipeline by Seattle Genetics, Inc., H1 2016 36

Pipeline by Zyrnat Biotherapeutics SL, H1 2016 37

Dormant Projects, H1 2016 57

Dormant Projects (Contd..1), H1 2016 58

Dormant Projects (Contd..2), H1 2016 59

Discontinued Products, H1 2016 60

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alligator Bioscience AB

Apexigen, Inc.

Apogenix GmbH

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celldex Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Kyowa Hakko Kirin Co., Ltd.

Novartis AG

Seattle Genetics, Inc.

Zyrnat Biotherapeutics SL

Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Therapeutic Products under Development, Key Players in Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Therapeutics, Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Pipeline Overview, Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Pipeline, Tumor Necrosis Factor Receptor Superfamily Member 5 (B-Cell Surface Antigen CD40 or CD40L Receptor or CD40) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com